Although no clinical trials directly targeting PKM2 have yet advanced to the registration stage in digestive system tumors, multiple preliminary mechanistic studies and animal model validations have provided a solid foundation for subsequent human trial design. This evidence concerns the gene PKM and digestive system neoplasm.